Literature DB >> 25287714

Abnormal liver function in different patients with Schistosoma japonicum.

An Ning1, Xiaoying Wu, Hongyu Li, Jinyi Liang, Zulu Gao, Jia Shen, Zhen Liu, Jun Xu, Fei Hu, Feng Wu, Pengyu Ji, Zhongdao Wu, Xi Sun.   

Abstract

Schistosomiasis japonica, caused by Schistosoma japonicum, is still a serious public health problem in China. It is important for schistosomiasis control to prevent from infection and advanced patients. Recent years, however, the form of the prevalence of schistosomiasis japonica in China was changed these days. Paying attention to the quality of life of these patients already infected with S. japonicum becomes a new objective to schistosomiasis control program. Although most of the chronic infections with S. japonicum will finally appear as liver fibrosis symptoms, it is still unknown liver function abnormalities in patients with severe forms of schistosomiasis, and there is also no evidence whether S. japonicum infection will directly cause damage to liver cells. Thus, this study investigated 494 patients diagnosed with S. japonicum (87.7%) and 69 healthy subjects from a endemic areas belonging to Jiangxi Province of China and aimed to evaluate the liver function abnormalities in patients with severe forms of schistosomiasis and possible associations with coinfection with HBV. The results showed that the hepatic metabolism situation significantly changed in patients infected with S. japonicum; meanwhile, the abnormal rates of ALT and AST in patients with schistosomiasis were significantly higher than that in the control group, which confirmed that patients infected with S. japonicum not only had damaged liver function but also the hepatic cells were directly influenced. And the coinfection of CHB and schistosomiasis japonica can be a risk factor for more serious outcomes in patients from endemic areas. These results give us the advice that in the further treatment of patients infected with S. japonicum, especially these coinfections, we should better give the routine liver-protection treatment in advance.

Entities:  

Mesh:

Year:  2014        PMID: 25287714     DOI: 10.1007/s00436-014-4163-7

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  18 in total

1.  The anatomical picture of the liver in hepato-splenic schistosomiasis mansoni.

Authors:  L BOGLIOLO
Journal:  Ann Trop Med Parasitol       Date:  1957-03

2.  Potential associations between perihepatic lymph node enlargement and liver fibrosis, hepatocellular injury or hepatocarcinogenesis in chronic hepatitis B virus infection.

Authors:  Masaya Sato; Hiromi Hikita; Shu Hagiwara; Mamiko Sato; Yoko Soroida; Atsushi Suzuki; Hiroaki Gotoh; Tomomi Iwai; Soichi Kojima; Tomokazu Matsuura; Hiroshi Yotsuyanagi; Kazuhiko Koike; Yutaka Yatomi; Hitoshi Ikeda
Journal:  Hepatol Res       Date:  2014-06-16       Impact factor: 4.288

3.  Hepatitis C and B virus in schistosomiasis patients on oral or parenteral treatment.

Authors:  Ahmed A El-Sabah; Mohamed T El-Metwally; Najlaa Y Abozinadah
Journal:  J Egypt Soc Parasitol       Date:  2011-08

4.  [Use of sodium azide, as feces preservative, for the study of eggs of Schistosoma mansoni by the Kato-Katz method].

Authors:  E M Gonçalves; R Campos; V Amato Neto; P L Pinta; A A Moreira
Journal:  Rev Soc Bras Med Trop       Date:  1988 Apr-Jun       Impact factor: 1.581

5.  Metabolic effects of a novel bioartificial liver on serum from severe hepatitis patients: an in vitro study.

Authors:  Feng Yan; Jun Zhao; Jiancang Ma; Zongfang Li; Qinghua Su
Journal:  Chin Med J (Engl)       Date:  2003-10       Impact factor: 2.628

6.  [Study on the influence factors of the serum fibrosis markers].

Authors:  Wei-min Cai; Jun Tao; Hong-lei Weng; Rong-hua Liu
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-01

7.  Influence factors of serum fibrosis markers in liver fibrosis.

Authors:  Jun Tao; Hui-Qin Peng; Wei-Min Cai; Feng-Qin Dong; Hong-Lei Weng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

8.  Monitoring the transmission of Schistosoma japonicum in potential risk regions of China, 2008 - 2012.

Authors:  Hui Dang; Jing Xu; Shi-Zhu Li; Zhi-Guo Cao; Yi-Xin Huang; Cheng-Guo Wu; Zu-Wu Tu; Xiao-Nong Zhou
Journal:  Int J Environ Res Public Health       Date:  2014-02-21       Impact factor: 3.390

9.  A description of the hepatitis B virus genomic background in a high-prevalence area in China.

Authors:  Xiaoming Chen; Jie Gao; Zhaohua Ji; Weilu Zhang; Lei Zhang; Rui Xu; Jingxia Zhang; Fei Li; Shi Li; Shijie Hu; Lei Shang; ZhongJun Shao; Yongping Yan
Journal:  Virol J       Date:  2014-05-31       Impact factor: 4.099

10.  Hepatitis B splice-generated protein antibodies in Syrian chronic hepatitis B patients: incidence and significance.

Authors:  Nour Al-Hanafi; Fawza Monem
Journal:  Hepat Mon       Date:  2014-04-16       Impact factor: 0.660

View more
  4 in total

1.  The expression of molecule CD28 and CD38 on CD4⁺/CD8⁺ T lymphocytes in thymus and spleen elicited by Schistosoma japonicum infection in mice model.

Authors:  Na Li; Peng-yu Ji; Lan-gui Song; Jun-xia Lei; Zhi-yue Lv; Zhong-dao Wu; Xiao Shao; Xi Sun
Journal:  Parasitol Res       Date:  2015-05-24       Impact factor: 2.289

2.  Characterization and expression analysis of Wnt5 in Schistosoma japonicum at different developmental stages.

Authors:  Na Ta; Xingang Feng; LingLing Deng; Zhiqiang Fu; Yang Hong; Jinming Liu; Hao Li; Ke Lu; Jiaojiao Lin; Chunxiu Yuan
Journal:  Parasitol Res       Date:  2015-06-17       Impact factor: 2.289

Review 3.  Research and control of advanced schistosomiasis japonica in China.

Authors:  Wei Wu; Aicheng Feng; Yixin Huang
Journal:  Parasitol Res       Date:  2014-11-19       Impact factor: 2.289

4.  New detection method in experimental mice for schistosomiasis: ClinProTool and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Yuzheng Huang; Wei Li; Kun Liu; Chunrong Xiong; Peng Cao; Jianping Tao
Journal:  Parasitol Res       Date:  2016-07-29       Impact factor: 2.289

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.